BCL2 and B-cell chronic lymphocytic leukemia: Although not mutated, upregulation of BCR, PI3K and BCL-2 anti-apoptotic molecules are involved in signaling pathways that drive CLL progression [11] and activate downstream effectors, e.g., JNK, ERK, mTOR, and NF-kB, which promote anti-apoptotic effects, growth, and proliferation [11–13].